Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by NotinKansason May 03, 2023 12:34am
264 Views
Post# 35426689

RE:Trial Result Tables

RE:Trial Result Tables
To identify the results achieved by the 12 initially undertreated one has to revisit the MD&A for full year 2021 (dated 28 April 2022). Here on page 5 they first present the results for all patients then treated, incl. those from Phase Ib (first table), and next the results for the optimized cohort alone, this time excl. Phase Ib (second table). If you deduct from the first table the two CRs and one NR from Phase Ib, and also the results from the optimized cohort (second table), you are left with the results achieved by the undertreated cohort alone. These amount to: 4CRs and 2IRs at 90D, 3CRs and 2IRs at 180D, 3CRs and 1IR at 270D, 2CRs and 1IR at 260 days, and 2CRs and 1IR at 450D. At that point in time, all first 12 patients had been in the trial for way over 450 days, so the most reasonable assumption would seem to be that these results for the undertreated are complete and final.
<< Previous
Bullboard Posts
Next >>